To include your compound in the COVID-19 Resource Center, submit it here.

Clinigen adds U.S. rights to Proleukin

Clinigen Group plc (LSE:CLIN) jumped 134.5p (18%) to 872p on Feb. 13 after the U.K. specialty pharma said it will acquire U.S. rights

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE